Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the extent of symptom remission in patients with trichotillomania following treatment with sertraline and/or behavior therapy.


Clinical Trial Description

The purpose of this study is to assess the extent of symptom remission in patients with trichotillomania following treatment with sertraline and/or behavior therapy.

Following entry into the study, subjects will undergo a washout period if they are currently taking a psychotropic medication (two weeks for psychotropic medications except for fluoxetine, which requires a four-week washout). Subjects will then be given a single-blind placebo for two weeks and assessed for symptom consistency.

Subjects will take sertraline or placebo in a double-blind design. Subjects will be assessed with the Hamilton Rating Scale for Depression (HAM-D-17), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Clinical Global Impressions Scale (CGI), Hair Pulling Scale (HPS), Trichotillomania (TTM) Impact Scale, Psychiatric Institute Trichotillomania Scale (PITS), National Institute of Mental Health (NIMH) Scale, and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) at the start of the washout period and at the end of week two in order to be randomized into the study. Subject randomization to a treatment arm will be based on the random table and in equal proportions.

Subject change scores will be assessed for the above scales, and change scores for the four different treatment groups will be assessed. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00118014
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Completed
Phase Phase 4
Start date January 2000
Completion date August 2004

See also
  Status Clinical Trial Phase
Completed NCT00115011 - Escitalopram for the Treatment of Self-Injurious Skin Picking Phase 4
Completed NCT02319395 - Behavioural Addiction and Genetics in Parkinson's Disease N/A
Recruiting NCT03970239 - Serotonin in Impulse Control Disorders in Parkinson's Disease N/A
Completed NCT03887429 - Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal Phase 2
Completed NCT02755181 - fMRI in Impulsivity
Completed NCT02722174 - Fingerprinting of Impulsivity
Enrolling by invitation NCT01354236 - Mental Health Related to School Dropout in Luxembourg N/A
Recruiting NCT02796040 - Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography. N/A
Not yet recruiting NCT02934919 - Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Phase 2